中源协和细胞基因工程股份有限公司2025年第二次临时股东大会决议公告

Meeting Summary - The second extraordinary general meeting of shareholders was held on December 15, 2025, at the company's conference room in Tianjin [2] - The meeting was presided over by Mr. Wang Hongqi, the vice chairman and general manager, and utilized a combination of on-site and online voting methods [2][3] Attendance - Out of 9 current directors, 6 attended the meeting, while the chairman and two independent directors were absent due to work commitments [3] - All 3 current supervisors attended the meeting, along with the acting secretary of the board and some senior executives and legal advisors [3] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the supervisory board and amendment of the Articles of Association [4] 2. Revision of the rules for shareholder meetings [4] 3. Revision of the rules for board meetings [5] 4. Abolition of the rules for supervisory board meetings [5] 5. Revision of the independent director work system [5] 6. Revision of the fundraising management system [5] 7. Revision of the related party transaction management system [5] 8. Revision of the internal control system for guarantees [5] 9. Revision of the internal control system for external investments [5] Voting Results - Resolutions 1, 2, 3, and 4 required a special resolution and were passed with over two-thirds of the valid voting rights held by attending shareholders or their representatives [6] Legal Verification - The meeting was witnessed by Beijing Guofeng Law Firm, and the lawyers confirmed that the meeting's procedures complied with relevant laws and regulations [7] Financial Management - The company utilized RMB 120 million of idle raised funds for cash management, specifically investing in structured deposits with Huaxia Bank [9][10] - The company redeemed the investment on December 15, 2025, recovering the principal of RMB 120 million and earning a profit of RMB 347,178.08 [10]